TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ”…
Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events…
SINGAPORE, May 27, 2025 (GLOBE NEWSWIRE) -- In a landmark announcement that bridges Asia and Europe, Leo International Group has…
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27,…
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday,…
BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed using Biolojic’s…
Results shared during a R&D Update featuring prominent experts in the field of ophthalmology A favorable safety profile plus significant…
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII),…
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events…